{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:37:20Z","timestamp":1793893040205,"version":"4.8.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In this systematic review and meta-analysis, we aimed to clarify the overall effects of functional foods and dietary supplements in non-alcoholic fatty liver disease (NAFLD) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Randomized controlled trials (RCTs) published in PubMed, ISI Web of Science, Cochrane library, and Embase from January 1, 2000 to January 31, 2022 were systematically searched to assess the effects of functional foods and dietary supplements in patients with NAFLD. The primary outcomes were liver-related measures, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatic fibrosis and steatosis, while the secondary outcomes included body mass index (BMI), waist circumference (WC), triacylglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). These indexes were all continuous variables, so the mean difference (MD) was used for calculating the effect size. Random-effects or fixed-effects models were used to estimate the mean difference (MD). The risk of bias in all studies was assessed with guidance provided in the Cochrane Handbook for Systematic Reviews of Interventions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-nine articles investigating functional foods and dietary supplements [antioxidants (phytonutrients and coenzyme Q10) = 18, probiotics\/symbiotic\/prebiotic = 6, fatty acids = 3, vitamin D = 1, and whole grain = 1] met the eligibility criteria. Our results showed that antioxidants could significantly reduce WC (MD: \u22121.28 cm; 95% CI: \u22121.58, \u22120.99, <jats:italic>P<\/jats:italic> &amp;lt; 0.05), ALT (MD: \u22127.65 IU\/L; 95% CI: \u221211.14, \u22124.16, <jats:italic>P<\/jats:italic> &amp;lt; 0.001), AST (MD: \u22124.26 IU\/L; 95% CI: \u22125.76, \u22122.76, <jats:italic>P<\/jats:italic> &amp;lt; 0.001), and LDL-C (MD: \u22120.24 mg\/dL; 95% CI: \u22120.46, \u22120.02, <jats:italic>P<\/jats:italic> &amp;lt; 0.05) increased in patients with NAFLD but had no effect on BMI, TG, and TC. Probiotic\/symbiotic\/prebiotic supplementation could decrease BMI (MD: \u22120.57 kg\/m<jats:sup>2<\/jats:sup>; 95% CI: \u22120.72, \u22120.42, <jats:italic>P<\/jats:italic> &amp;lt; 0.05), ALT (MD: \u22123.96 IU\/L; 95% CI: \u22125.24, \u22122.69, <jats:italic>P<\/jats:italic> &amp;lt; 0.001), and AST (MD: \u22122.76; 95% CI: \u22123.97, \u22121.56, <jats:italic>P<\/jats:italic> &amp;lt; 0.0001) levels but did not have beneficial effects on serum lipid levels compared to the control group. Moreover, the efficacy of fatty acids for treating NAFLD was full of discrepancies. Additionally, vitamin D had no significant effect on BMI, liver transaminase, and serum lipids, while whole grain could reduce ALT and AST but did not affect serum lipid levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The current study suggests that antioxidant and probiotic\/symbiotic\/prebiotic supplements may be a promising regimen for NAFLD patients. However, the usage of fatty acids, vitamin D, and whole grain in clinical treatment is uncertain. Further exploration of the efficacy ranks of functional foods and dietary supplements is needed to provide a reliable basis for clinical application.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero<\/jats:ext-link>, identifier: CRD42022351763.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2023.1014010","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T18:02:42Z","timestamp":1676397762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Lei-lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pian-hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-hui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.07.045","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/MPG.0000000000001624","article-title":"Systematic review: nutrition and physical activity in the management of paediatric nonalcoholic fatty liver disease","volume":"65","author":"Gibson","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu9101124","article-title":"Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy","volume":"9","author":"Ma","year":"2017","journal-title":"Nutrients"},{"key":"B4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.dld.2021.04.029","article-title":"Non-alcoholic fatty liver disease in adults 2021: a clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)","volume":"54","author":"Marchesini","year":"2022","journal-title":"Digest Liver Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3760\/cma.j.issn.1007-3418.2018.03.008","article-title":"Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update","volume":"31","year":"2018","journal-title":"Infect Dis Info"},{"key":"B7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","article-title":"The epidemiology of NAFLD in mainland china with analysis by adjusted gross regional domestic product: a meta-analysis","volume":"14","author":"Wu","year":"2020","journal-title":"Hepatol Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"59","year":"2016","journal-title":"Diabetologia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/MEG.0000000000001135","article-title":"Lifestyle interventions for patients with nonalcoholic fatty liver disease: a network meta-analysis","volume":"30","author":"Zou","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.metabol.2016.12.006","article-title":"Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"68","author":"Katsagoni","year":"2017","journal-title":"Metabolism."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms9050957","article-title":"Gut microbiota and nafld: Pathogenetic mechanisms, microbiota signatures, and therapeutic interventions","volume":"9","author":"Hrncir","year":"2021","journal-title":"Microorganisms"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?","volume":"158","author":"Aron-Wisnewsky","year":"2020","journal-title":"Gastroenterology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human nafld: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/MEG.0000000000001371","article-title":"The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis","volume":"31","author":"Khan","year":"2019","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B17","unstructured":"Regression of non-alcoholic fatty liver by vitamin d supplement: a double-blind randomized controlled clinical trial6318\n            AminHL\n            AgahS\n            MousaviSN\n            HosseiniAF\n            ShidfarF\n          27631178Arch Iran Med.192016"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD013157.pub2","article-title":"Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis","volume":"7","author":"Komolafe","year":"2021","journal-title":"Cochr Database Syst Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu10091153","article-title":"Nutraceutical approach to non-alcoholic fatty liver disease (nafld): the available clinical evidence","volume":"10","author":"Cicero","year":"2018","journal-title":"Nutrients"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.2147\/DMSO.S254555","article-title":"Therapeutic effects of garlic on hepatic steatosis in nonalcoholic fatty liver disease patients: a randomized clinical trial","volume":"13","author":"Soleimani","year":"2020","journal-title":"Diabetes Metabolic Syndr Obes Targets Therapy."},{"key":"B21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ctim.2019.04.014","article-title":"Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial","volume":"44","author":"Darand","year":"2019","journal-title":"Comp Ther Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"101259","DOI":"10.1016\/j.ctcp.2020.101259","article-title":"Eslami O. The effects of sumac (Rhus coriarial) powder supplementation in patients with non-alcoholic fatty liver disease: A randomized controlled trial","volume":"41","author":"Kazemi","year":"2020","journal-title":"Comp Ther Clin Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1017\/S0007114520001403","article-title":"Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial","volume":"124","author":"Sangouni","year":"2020","journal-title":"Br J Nutr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00210-022-02234-2","article-title":"Phytochemicals targeting nafld through modulating the dual function of forkhead box o1 (foxo1) transcription factor signaling pathways Naunyn Schmiedebergs","volume":"395","author":"Sabir","year":"2022","journal-title":"Arch Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1024\/0300-9831\/a000292","article-title":"Effects of pomegranate and orange juice on antioxidant status in non-alcoholic fatty liver disease patients: a randomized clinical trial","volume":"85","author":"Ekhlasi","year":"2015","journal-title":"Int J Vitamin Nutr Res."},{"key":"B26","article-title":"Special topics in statistics","author":"Higgins","year":"2011","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in cochrane reviews: the robes meta-epidemiologic study","volume":"187","author":"Savovic","year":"2018","journal-title":"Am J Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/epi.13989","article-title":"Cochrane systematic review and meta-analysis of the impact of psychological treatments for people with epilepsy on health-related quality of life","volume":"59","author":"Michaelis","year":"2018","journal-title":"Epilepsia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome\u2013targeted therapies in nonalcoholic fatty liver disease","volume":"110","author":"Suzanne","year":"2019","journal-title":"Am J Clin Nutr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2008-7802.173051","article-title":"The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease","volume":"7","author":"Pezeshki","year":"2015","journal-title":"Int J Prev Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.7762\/cnr.2020.9.4.258","article-title":"A randomized, double-blind, placebo-controlled, multi-centered clinical study to evaluate the efficacy and safety of artemisia annua l. Extract for improvement of liver function","volume":"9","author":"Han","year":"2020","journal-title":"Clin Nutr Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/ptr.6937","article-title":"Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: a randomized clinical trial","volume":"35","author":"Soleimani","year":"2021","journal-title":"Phytotherapy Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nutres.2013.11.005","article-title":"Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity c-reactive protein in nonalcoholic fatty liver disease patients","volume":"34","author":"Askari","year":"2014","journal-title":"Nutr Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/ptr.6826","article-title":"Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with non-alcoholic fatty liver disease: a double-blind randomized controlled clinical trial","volume":"35","author":"Izadi","year":"2021","journal-title":"Phytother Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2337\/dc14-2852","article-title":"Improvement of nonalcoholic fatty liver disease with carnitine-orotate complex in type 2 diabetes (corona) a randomized controlled trial","volume":"38","author":"Bae","year":"2015","journal-title":"Diabetes Care."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1108\/NFS-10-2019-0321","article-title":"Quercetin supplementation in non-alcoholic fatty liver disease a randomized, double-blind, placebo-controlled clinical trial","volume":"50","author":"Hosseinikia","year":"2020","journal-title":"Nutr Food Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/07315724.2018.1466739","article-title":"Effects of phytosterol supplementation on serum levels of lipid profiles, liver enzymes, inflammatory markers, adiponectin, and leptin in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial","volume":"37","author":"Mohammad Shahi","year":"2018","journal-title":"J Am Coll Nutr."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1097\/MD.0000000000000758","article-title":"A consort-compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine."},{"key":"B39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/07315724.2016.1267597","article-title":"Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases","volume":"36","author":"Navekar","year":"2017","journal-title":"J Am Coll Nutr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00394-019-01916-7","article-title":"Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial","volume":"59","author":"Cicero","year":"2020","journal-title":"Eur J Nutr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e14852","DOI":"10.1111\/ijcp.14852","article-title":"Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight\/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial","volume":"75","author":"Namkhah","year":"2021","journal-title":"Int J Clin Pract."},{"key":"B42","unstructured":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial10905\n            AllerR\n            De LuisDA\n            IzaolaO\n            CondeR\n            Gonzalez SagradoM\n            PrimoD\n          22013734Eur Rev Med Pharmacol Sci.152011"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2008-7802.178533","article-title":"The effect of symbiotic supplementation on liver enzymes, c-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial","volume":"7","author":"Asgharian","year":"2016","journal-title":"Int J Prev Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP (\u00ae) BCMC (\u00ae) strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","article-title":"randomised placebo controlled trial of VSL#3(\u00ae) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3329\/bjp.v11i1.24513","article-title":"Effects of coenzyme q10 supplementation on the anthropometric variables, lipid profiles and liver enzymes in patients with nonalcoholic fatty liver disease","volume":"11","author":"Jafarvand","year":"2016","journal-title":"Bangladesh J Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/07315724.2015.1021057","article-title":"Functions of coenzyme q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial","volume":"35","author":"Farsi","year":"2016","journal-title":"J Am Coll Nutr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.arcmed.2014.11.001","article-title":"Oral coenzyme q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress","volume":"45","author":"Farhangi","year":"2014","journal-title":"Arch Med Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40200-019-00439-6","article-title":"The effect of nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver","volume":"18","author":"Rashidmayvan","year":"2019","journal-title":"J Diabetes Metab Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu12113372","article-title":"Impact of long-term supplementation with fish oil in individuals with non-alcoholic fatty liver disease: a double blind randomized placebo controlled clinical trial","volume":"12","author":"Cansan\u00e7\u00e3o","year":"2020","journal-title":"Nutrients"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the welcome* study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12916-016-0638-y","article-title":"No effects of oral vitamin d supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Barchetta","year":"2016","journal-title":"BMC Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1017\/S0007114519002769","article-title":"Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial","volume":"123","author":"Masoumeh","year":"2020","journal-title":"Br J Nutr."},{"key":"B56","doi-asserted-by":"publisher","first-page":"667","DOI":"10.4314\/ahs.v13i3.21","article-title":"Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver","volume":"13","author":"Al-Jiffri","year":"2013","journal-title":"Afr Health Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Sana","year":"2021","journal-title":"Front Biosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/biom10121702","article-title":"Oxidative stress in NAFLD: role of nutrients and food contaminants","volume":"10","author":"Rives","year":"2020","journal-title":"Biomolecules."},{"key":"B59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity","volume":"16","author":"Robert","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3945\/an.116.014050","article-title":"Effects of dietary flavonoids on reverse cholesterol transport, HDL metabolism, and HDL function","volume":"8","author":"Millar","year":"2017","journal-title":"Adv Nutr."},{"key":"B61","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1024\/0300-9831\/a000675","article-title":"Dietary total antioxidant capacity (TAC), general and central obesity indices and serum lipids among adults: An updated systematic review and meta-analysis","volume":"92","author":"Farhangi","year":"2022","journal-title":"Int J Vitam Nutr Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1080\/10408398.2018.1458021","article-title":"Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: synbiotic supplementation and NAFLD","volume":"59","author":"Amir","year":"2019","journal-title":"Crit Rev Food Sci Nutr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J Hepatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"Cd011564","DOI":"10.1002\/14651858.CD011564.pub3","article-title":"Vitamin d supplementation for chronic liver diseases in adults","volume":"8","author":"Bjelakovic","year":"2021","journal-title":"Cochr Database Syst Rev."},{"key":"B66","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1017\/S000711451300305X","article-title":"Combining functional features of whole-grain barley and legumes for dietary reduction of cardiometabolic risk: a randomised cross-over intervention in mature women","volume":"111","author":"Tovar","year":"2014","journal-title":"Br J Nutr."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/jn\/nxz071","article-title":"Glucose- and lipid-related biomarkers are affected in healthy obese or hyperglycemic adults consuming a whole-grain pasta enriched in prebiotics and probiotics: a 12-week randomized controlled trial","volume":"149","author":"Angelino","year":"2019","journal-title":"J Nutr."},{"key":"B68","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1039\/D0FO01095B","article-title":"Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Guo","year":"2020","journal-title":"Food Funct."},{"key":"B69","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12020-014-0336-5","article-title":"Does vitamin d improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial","volume":"47","author":"Sharifi","year":"2014","journal-title":"Endocrine."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1014010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T18:02:50Z","timestamp":1676397770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1014010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":69,"alternative-id":["10.3389\/fnut.2023.1014010"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2023.1014010","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"article-number":"1014010"}}